{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:59:50Z","timestamp":1775609990446,"version":"3.50.1"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health","award":["ZIA BC011525"],"award-info":[{"award-number":["ZIA BC011525"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Recurrent endometrial cancer (EC) has limited therapeutic options beyond platinum-based chemotherapy, highlighting the need to identify exploitable molecular vulnerabilities. Tumors with high genomic instability, including microsatellite instability-high (MSI-h) or copy-number-high (CNH) ECs, rely on the ATR-CHK1 signaling pathway to tolerate replication stress and maintain genome integrity, making this pathway an attractive therapeutic target. However, acquired resistance to ATR and CHK1 inhibitors (ATRi\/CHK1i) often develops, and the transcriptomic basis of this resistance in EC remains unknown. Here, we established isogenic ATRi- and CHK1i-resistant cell line models from MSI-h (HEC1A) and CNH (ARK2) EC lineages and performed baseline transcriptomic profiling to characterize stable resistance-associated states. MSI-h-derived resistant clones adopted a unified transcriptional state enriched for epithelial-mesenchymal transition, cytokine signaling, and interferon responses, while ATRi-resistant models showing additional enrichment of developmental and KRAS\/Notch-associated pathways. In contrast, CNH-derived resistant clones diverged by inhibitor class, with ATRi resistance preferentially enriching proliferation-associated pathways and CHK1i resistance inducing interferon signaling. Notably, THBS1, EDN1, and TENM2 were consistently upregulated across all resistant models relative to parental lines. Together, these findings demonstrate that acquired resistance to ATRi and CHK1i in EC is shaped by both lineage and inhibitor class and provide a transcriptomic framework that may inform future biomarker development and therapeutic strategies.<\/jats:p>","DOI":"10.3390\/biom16010169","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:27:58Z","timestamp":1768908478000},"page":"169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptional Profiling Reveals Lineage-Specific Characteristics in ATR\/CHK1 Inhibitor-Resistant Endometrial Cancer"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-2760","authenticated-orcid":false,"given":"Tzu-Ting","family":"Huang","sequence":"first","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2025). Cancer Facts & Figures 2025, American Cancer Society, Inc.. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf."},{"key":"ref_3","first-page":"1","article-title":"Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options","volume":"40","author":"MacKay","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_4","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhao, L., Li, X., Jing, Y., Tang, L., Lin, F., Zhang, Y., Tang, Y., Chen, C., Yang, J., and Liu, X. (2025). Biomarkers and immunotherapy in endometrial cancer: Mechanisms and clinical applications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1684549"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","article-title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: Interim results from GARNET-a phase I, single-arm study","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373.","DOI":"10.1038\/nature12113"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Baiden-Amissah, R.E.M., Annibali, D., Tuyaerts, S., and Amant, F. (2021). Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. Cancers, 13.","DOI":"10.3390\/cancers13163988"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2020.01.008","article-title":"Histopathological characterization of ProMisE molecular groups of endometrial cancer","volume":"157","author":"Raffone","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00404-020-05542-1","article-title":"Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1101\/gad.351084.123","article-title":"ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy","volume":"37","author":"Wang","year":"2023","journal-title":"Genes Dev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rundle, S., Bradbury, A., Drew, Y., and Curtin, N.J. (2017). Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers, 9.","DOI":"10.3390\/cancers9050041"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106162","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: A first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eadd7872","DOI":"10.1126\/scitranslmed.add7872","article-title":"BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer","volume":"15","author":"Gupta","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: A phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.annonc.2024.08.805","article-title":"744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)","volume":"35","author":"Lee","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","article-title":"A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors","volume":"62","author":"Ruiz","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","article-title":"Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2","volume":"82","author":"Chen","year":"2022","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"ref_24","first-page":"980","article-title":"EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer","volume":"3","author":"Lee","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/jop.12430","article-title":"THBS1 is induced by TGFB1 in the cancer stroma and promotes invasion of oral squamous cell carcinoma","volume":"45","author":"Pal","year":"2016","journal-title":"J. Oral. Pathol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"121185","DOI":"10.1016\/j.biomaterials.2021.121185","article-title":"ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1","volume":"279","author":"Patwardhan","year":"2021","journal-title":"Biomaterials"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2020.08.026","article-title":"Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer","volume":"492","author":"Tocci","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1158\/0008-5472.CAN-13-3133","article-title":"Endothelin A receptor\/beta-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy","volume":"74","author":"Rosano","year":"2014","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"Bailey","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gorecki, L., Andrs, M., and Korabecny, J. (2021). Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13040795"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s41065-025-00564-8","article-title":"Cancer cell plasticity and therapeutic resistance: Mechanisms, crosstalk, and translational perspectives","volume":"162","author":"Ghorbian","year":"2025","journal-title":"Hereditas"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aas9090","article-title":"NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination","volume":"362","author":"Ruscetti","year":"2018","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","article-title":"CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer","volume":"159","author":"Chipumuro","year":"2014","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.chembiol.2025.07.004","article-title":"Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers","volume":"32","author":"Yang","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11795549251384582","DOI":"10.1177\/11795549251384582","article-title":"Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights","volume":"19","author":"Catalano","year":"2025","journal-title":"Clin. Med. Insights Oncol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:54:13Z","timestamp":1768910053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["biom16010169"],"URL":"https:\/\/doi.org\/10.3390\/biom16010169","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}